Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. director John H. Sampson received an equity award of 773 restricted stock units on February 10, 2026. The Form 4 reports this as an acquisition of derivative securities at a price of $0 per unit, held as direct beneficial ownership.
Each restricted stock unit represents the contingent right to receive one share of Labcorp common stock. The 773 restricted stock units vest fully on February 10, 2027, and the filing shows 773 derivative securities beneficially owned following the reported transaction.
Labcorp Holdings Inc. director Kathryn E. Wengel received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported at a price of $0 per unit as a grant, not an open-market purchase.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp common stock, and the units vest fully on February 10, 2027. Following this grant, Wengel beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Richelle P. Parham received a new equity award in the form of restricted stock units. On February 10, 2026, she acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock, at no cash cost.
The Restricted Stock Units vest fully on February 10, 2027, meaning the shares will be delivered if the vesting conditions are satisfied. After this grant, Parham beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Peter M. Neupert reported an equity award under a company plan. On February 10, 2026, he received 773 Restricted Stock Units (RSUs) at a price of $0 per unit. Each RSU represents the right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning he will receive the underlying shares if vesting conditions are met. After this grant, Neupert beneficially owns 1,670 RSUs in total, all held as direct ownership.
Labcorp Holdings Inc. director Kirsten M. Kliphouse acquired 773 Restricted Stock Units on February 10, 2026 as an equity grant. Each unit represents the right to receive one share of Labcorp common stock. These units vest in full on February 10, 2027, subject to the award terms.
Following this grant, Kliphouse beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership. The transaction was reported as a grant, award, or other acquisition at a price of $0 per unit.
Labcorp Holdings Inc. director Jeffrey A. Davis received an equity grant of 773 Restricted Stock Units on February 10, 2026. Each unit represents the right to receive one share of Labcorp common stock. The Restricted Stock Units vest fully on February 10, 2027.
After this award, Davis beneficially owns a total of 1,670 Restricted Stock Units in Labcorp through direct ownership, reflecting his aggregate RSU holdings as reported.
Labcorp Holdings Inc. director Victor Bulto Carulla was granted 773 Restricted Stock Units (RSUs) on February 10, 2026, as reported in a Form 4 insider filing. Each RSU represents the contingent right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning the director must remain eligible through that date to receive the underlying shares. Following this grant, the director beneficially owns 909 RSUs in total, all held in a direct ownership capacity.
Labcorp Holdings Inc. director Kerrii B. Anderson received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported as an acquisition of derivative securities at a price of $0 per unit under a standard grant or award transaction code.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. common stock. These units vest fully on February 10, 2027. Following this grant, Anderson beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership.
A holder of Laboratory Corporation of America Holdings (LH) common stock has filed a Rule 144 notice to sell 87 shares through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 02/12/2026 and an aggregate market value of $25,266.54.
The 87 shares were acquired on 02/11/2026 via restricted stock vesting from the issuer as compensation. In the past three months, Jonathan Meltzer sold LH common stock in two transactions: 88 shares on 02/09/2026 for $24,246.64 and 91 shares on 02/10/2026 for $25,187.89.
An insider has filed a Form 144 notice indicating an intention to sell up to 5,273 shares of common stock, with an aggregate market value of $1,499,535.74. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/11/2026.
The securities to be sold were acquired via restricted stock vesting from the issuer on 02/02/2024 (361 shares) and 03/27/2024 (4,912 shares), as compensation. The notice also lists a prior sale of 5,745 shares of common stock on 11/11/2025 for gross proceeds of $1,509,498.75.